Abstract
Novel clinical strategies need to be evolved, as pathogens, especially the ones that infect the human, develop resistance. To do so, host pathogen biology needs to be clearly understood and this can be done using a nematode worm, Caenorhabditis elegans, which harbours the same virulent microbes. Over several decades, the worm has been used to study host-microbe interaction with reference to immune response of the worm, antimicrobial molecules secreted, cell death in the worm body, quorum sensing network of the bacteria and fast or slow worm death. This mini review gives a bird’s eye view of the directions that have been taken in these areas to date. Currently, the worm has been proposed to be an ideal model for high throughput screening of natural and synthetic drugs against a variety of bacteria. Experimental systems that allow this screening have been patented. Caenorhabditis elegans, thus, is one of the very effective models for studying pathogens that infect human.
Keywords: Anti-bacterial molecules, Caenorhabditis elegans, drug screening, human gut pathogens, innate immunity model organism.
Recent Patents on Biotechnology
Title:Caenorhabditis elegans: A Model for Studying Human Pathogen Biology
Volume: 10 Issue: 2
Author(s): Nabila Sorathia and Medha S. Rajadhyaksha
Affiliation:
Keywords: Anti-bacterial molecules, Caenorhabditis elegans, drug screening, human gut pathogens, innate immunity model organism.
Abstract: Novel clinical strategies need to be evolved, as pathogens, especially the ones that infect the human, develop resistance. To do so, host pathogen biology needs to be clearly understood and this can be done using a nematode worm, Caenorhabditis elegans, which harbours the same virulent microbes. Over several decades, the worm has been used to study host-microbe interaction with reference to immune response of the worm, antimicrobial molecules secreted, cell death in the worm body, quorum sensing network of the bacteria and fast or slow worm death. This mini review gives a bird’s eye view of the directions that have been taken in these areas to date. Currently, the worm has been proposed to be an ideal model for high throughput screening of natural and synthetic drugs against a variety of bacteria. Experimental systems that allow this screening have been patented. Caenorhabditis elegans, thus, is one of the very effective models for studying pathogens that infect human.
Export Options
About this article
Cite this article as:
Sorathia Nabila and Rajadhyaksha S. Medha, Caenorhabditis elegans: A Model for Studying Human Pathogen Biology, Recent Patents on Biotechnology 2016; 10 (2) . https://dx.doi.org/10.2174/1872208310666160727151853
DOI https://dx.doi.org/10.2174/1872208310666160727151853 |
Print ISSN 1872-2083 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-4012 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Role of Molecular Analysis After Autopsy Negative Sudden Death in the Young
Current Pediatric Reviews Structural Insights into Chitinolytic Enzymes and Inhibition Mechanisms of Selective Inhibitors
Current Pharmaceutical Design The Importance of Guidelines in the Development and Application of Probiotics
Current Pharmaceutical Design Daptomycin: A Review of Properties, Clinical Use, Drug Delivery and Resistance
Mini-Reviews in Medicinal Chemistry Endophthalmitis
Anti-Infective Agents in Medicinal Chemistry How Do Periodontal Infections Affect the Onset and Progression of Alzheimer’s Disease?
CNS & Neurological Disorders - Drug Targets Antimicrobial Peptides and Peptidomimetics - Potent Therapeutic Allies for Staphylococcal Infections
Current Pharmaceutical Design Disseminated TB in an Immunocompetent Patient: A Case Report
Infectious Disorders - Drug Targets Indications for Surgery and Operative Techniques in Infective Endocarditis in the Present Day
Infectious Disorders - Drug Targets Occurrence and Clinical Impact of Microembolic Signals (MES) in Patients with Chronic Cardiac Diseases and Atheroaortic Plaques - A Systematic Review
Current Vascular Pharmacology Toll-Like Receptors in Skin Infections and Inflammatory Diseases
Infectious Disorders - Drug Targets Hyperglycemia, Hypoglycemia and Dementia: Role of Mitochondria and Uncoupling Proteins
Current Molecular Medicine An Update to Enterococcal Bacteremia: Epidemiology, Resistance, and Outcome
Infectious Disorders - Drug Targets Complex Atheromatosis of the Aortic Arch in Cerebral Infarction
Current Cardiology Reviews Vasopressin and Terlipressin in Neonates and Children with Refractory Septic Shock
Current Drug Metabolism The Role of Diffusion- and Perfusion-Weighted Magnetic Resonance Imaging in Drug Development for Ischemic Stroke: From Laboratory to Clinics
Current Vascular Pharmacology The Role of 18FDG PET/CT in the Assessment of Endocarditis, Myocarditis and Pericarditis
Current Radiopharmaceuticals Vaccines and Photodynamic Therapies for Oral Microbial-Related Diseases
Current Drug Metabolism Bacterial Zinc Proteases and their Inhibition
Current Enzyme Inhibition Non-Microbicidal Control of Bacterial Biofilms with Small Molecules
Anti-Infective Agents